MARKET

OCX

OCX

ONCOCYTE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.910
+0.210
+5.68%
Closed 17:16 09/27 EDT
OPEN
3.730
PREV CLOSE
3.700
HIGH
3.980
LOW
3.670
VOLUME
353.38K
TURNOVER
--
52 WEEK HIGH
6.57
52 WEEK LOW
1.310
MARKET CAP
358.08M
P/E (TTM)
-10.8883
1D
5D
1M
3M
1Y
5Y
How Bad Are OncoCyte Corporation Common Stock's Earnings? | Return On Capital Employed
Benzinga Pro data, OncoCyte Corporation Common Stock (AMEX:OCX) reported Q2 sales of $2.03 million. Earnings fell to a loss of $13.57 million, resulting in a 19.44% decrease from last quarter.
Benzinga · 5d ago
Oncocyte Announces Oral Presentation of New Data on Its DetermaIO™ Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting
Randomized clinical trial data from NeoTRIPaPDL1 study establishes DetermaIO as a predictive biomarker of immunotherapy response Trial Investigators found DetermaIO outperformed 80 other immune related signatures in TNBC IRVINE, Calif., Sept. 20, 2021 (GLO...
GlobeNewswire · 09/20 15:35
OncoCyte Says Trial Data Showed DetermaIO's Potential as Predictive Biomarker of Immunotherapy Response
MT Newswires · 09/20 15:10
Oncocyte Hosting Two-Part Key Opinion Leader Event Series
Part 1: Transplant Rejection Testing – Wednesday, September 22nd @ 1pmET Part 2: DetermaIO™ in Triple-Negative Breast Cancer – Tuesday, September 28th @ 1pmET IRVINE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precisio...
GlobeNewswire · 09/20 12:00
Modern Healthcare Recognizes Oncocyte as One of the 2021 Best Places to Work in Healthcare
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, announced toda...
GlobeNewswire · 09/16 12:00
Modern Healthcare Recognizes Oncocyte as One of the 2021 Best Places to Work in Healthcare
CHICAGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatme...
GlobeNewswire · 09/16 12:00
BRIEF-Oncocyte to Present New Data on DetermaIO in Oral Presentation from Late-Breaking Abstract at ESMO 2021
reuters.com · 09/13 13:24
Oncocyte To Present New Data On DetermaIO From NeoTRIPaPDL1 Trial In Oral Presentation From Late-Breaking Abstract At ESMO 2021 Sept. 20
Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment,
Benzinga · 09/13 12:08
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCX. Analyze the recent business situations of ONCOCYTE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OCX stock price target is 9.00 with a high estimate of 11.00 and a low estimate of 7.00.
High11.00
Average9.00
Low7.00
Current 3.910
EPS
Actual
Estimate
-0.10-0.07-0.05-0.02
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 112
Institutional Holdings: 59.49M
% Owned: 64.96%
Shares Outstanding: 91.58M
TypeInstitutionsShares
Increased
26
3.09M
New
14
825.35K
Decreased
34
1.33M
Sold Out
10
528.12K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.10%
Pharmaceuticals & Medical Research
-0.86%
Key Executives
Non-Executive Chairman/Independent Director
Cavan Redmond
President/Chief Executive Officer/Director
Ronald Andrews
Chief Financial Officer
Mitchell Levine
Chief Accounting Officer/Vice President/Controller
Li Yu
Other
Douglas Ross
Other
Padma Sundar
Independent Director
Andrew Arno
Independent Director
Jennifer Carter
Independent Director
Melinda Griffith
Independent Director
Alfred Kingsley
Independent Director
Andrew Last
No Data
About OCX
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.

Webull offers kinds of Oncocyte Corporation stock information, including NASDAQ:OCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCX stock methods without spending real money on the virtual paper trading platform.